The alpha-2-Heremans-Schmid Glycoprotein (AHSG), also known as alpha-2-HS-Glycoprotein, or fetuin-A, is a highly glycosylated plasma protein synthesized in liver and enriched in bone (1). AHSG is an abundant serum protein with powerful calcification inhibitory properties. AHSG deficiency was recently linked to cardiovascular mortality in dialysis patients (2,3). While increased fetuin-A levels positively correlated with vascular calcification in patients with diabetes and mild to moderate renal impairment, an inverse relationship was observed in dialysis patients. Both chronic inflammation and uremia may contribute to exhausting fetuin-A release in the late stages of kidney disease (4). It has been recently reported AHSG to be decreased in the cerebrospinal fluid of patients with Alzheimer's disease (5).